Evidence map›Paper›PMID 41634778›Full record

ArticleJournal of neuroinflammation2026

Peripheral immunosuppressive and immunostimulatory signatures of severity and pain in spinal cord injury.

Jayden A O'Brien, Frederick A Collin, Ava C Mason, Rebecca V Robertson, Sachin Shetty, Iain S McGregor, Luke A Henderson, Paul J Austin

Abstract read
In one paragraph

Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jayden A O'Brien *Brain and Mind Centre, Neuroscience Theme, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia.
Frederick A Collin *Brain and Mind Centre, Neuroscience Theme, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia.
Ava C MasonBrain and Mind Centre, Neuroscience Theme, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia.
Rebecca V RobertsonBrain and Mind Centre, Neuroscience Theme, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia.
Sachin ShettySpinal Injuries Unit and Pain Management, Prince of Wales Hospital, New South Wales, Australia.
Iain S McGregorLambert Initiative for Cannabinoid Therapeutics, University of Sydney, New South Wales, Australia.
Luke A HendersonBrain and Mind Centre, Neuroscience Theme, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia.
Paul J AustinBrain and Mind Centre, Neuroscience Theme, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia. paul.austin@sydney.edu.au.

Funding

NSW Health Office for Health and Medical Research G207182
6 · The paper itself

Abstract

Spinal cord injury is a severe neurological condition associated with an increased risk of infection, an elevated mortality rate, and often results in chronic neuropathic pain. The peripheral immune changes in the chronic phase of spinal cord injury are largely unknown, as is their capacity to facilitate neuropathic pain. The current study used a high-dimensional single-cell analysis of peripheral blood to evaluate major immune populations and functional markers in individuals with chronic spinal injury. Spinal cord injury was associated with a shift towards classical monocytes and an increase in granulocytic myeloid-derived suppressor cells. There were also reductions in NK cells and B cells, as well as impairments to memory T cell functioning. The elevation of classical monocytes and decrease in NK cells were more pronounced in injured individuals with neuropathic pain, a high spinal level of lesion, and a moderate, but not severe injury. These findings highlight the cell-specific systemic immune dysfunction in chronic spinal cord injury and how more severe clinical subgroups are largely associated with greater immune impairment. Therefore, targeting immune dysfunction may lead to an improvement in symptom severity, whilst biomarkers of immune dysfunction may be useful in predicting the clinical trajectory.

Indexed as

NeuralgiaSpinal Cord InjuriesAdultFemaleHumansKiller Cells, NaturalMaleMiddle AgedMonocytesSeverity of Illness Index

Identifiers

PMID41634778
PMCPMC12954965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.